Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody

J. A. Carrasquillo, P. A. Bunn, A. M. Keenan, J. C. Reynolds, R. W. Schroff, K. A. Foon, M. H. Su, A. F. Gazdar, J. L. Mulshine, R. K. Oldham

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

T101 monoclonal antibody recognizes a pan-T-cell antigen present on normal T cells and also found in high concentrations in cutaneous T-cell lymphoma. We used this antibody, radiolabeled with 111In, in gamma-camera imaging to detect sites of metastatic cutaneous T-cell lymphoma in 11 patients with advanced disease. In all patients, [111In]T101 concentrated in pathologically or clinically detected nodes, including those in several previously unsuspected nodal regions. Concentrations (per gram of tissue) ranged from 0.01 to 0.03 percent of the injected dose and were consistently 10 to 100 times higher than previously reported on radioimmunodetection. Focal uptake was seen in skin tumors and heavily infiltrated erythroderma but not in skin plaques. The specificity of tumor targeting was documented by control studies with [111In]chloride or [111In]9.2.27 (anti-melanoma) monoclonal antibody. Increasing the T101 dose (1 to 50 mg) altered distribution in nontumor tissues. These studies suggest that imaging with [111In]T101 may be of value in identifying sites of cutaneous T-cell lymphoma. In contrast to the targeting of solid tumors, the mechanism of localization appears to be related to binding to T cells, which can then carry the radioactivity to involved sites.

Original languageEnglish (US)
Pages (from-to)673-680
Number of pages8
JournalNew England Journal of Medicine
Volume315
Issue number11
StatePublished - 1986

Fingerprint

Radioimmunodetection
Cutaneous T-Cell Lymphoma
Monoclonal Antibodies
T-Lymphocytes
Exfoliative Dermatitis
Neoplasms
Skin
Viral Tumor Antigens
Radionuclide Imaging
Radioactivity
Chlorides
Melanoma
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Carrasquillo, J. A., Bunn, P. A., Keenan, A. M., Reynolds, J. C., Schroff, R. W., Foon, K. A., ... Oldham, R. K. (1986). Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. New England Journal of Medicine, 315(11), 673-680.

Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. / Carrasquillo, J. A.; Bunn, P. A.; Keenan, A. M.; Reynolds, J. C.; Schroff, R. W.; Foon, K. A.; Su, M. H.; Gazdar, A. F.; Mulshine, J. L.; Oldham, R. K.

In: New England Journal of Medicine, Vol. 315, No. 11, 1986, p. 673-680.

Research output: Contribution to journalArticle

Carrasquillo, JA, Bunn, PA, Keenan, AM, Reynolds, JC, Schroff, RW, Foon, KA, Su, MH, Gazdar, AF, Mulshine, JL & Oldham, RK 1986, 'Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody', New England Journal of Medicine, vol. 315, no. 11, pp. 673-680.
Carrasquillo JA, Bunn PA, Keenan AM, Reynolds JC, Schroff RW, Foon KA et al. Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. New England Journal of Medicine. 1986;315(11):673-680.
Carrasquillo, J. A. ; Bunn, P. A. ; Keenan, A. M. ; Reynolds, J. C. ; Schroff, R. W. ; Foon, K. A. ; Su, M. H. ; Gazdar, A. F. ; Mulshine, J. L. ; Oldham, R. K. / Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. In: New England Journal of Medicine. 1986 ; Vol. 315, No. 11. pp. 673-680.
@article{86d9ce139981453281fff6edd3b5a914,
title = "Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody",
abstract = "T101 monoclonal antibody recognizes a pan-T-cell antigen present on normal T cells and also found in high concentrations in cutaneous T-cell lymphoma. We used this antibody, radiolabeled with 111In, in gamma-camera imaging to detect sites of metastatic cutaneous T-cell lymphoma in 11 patients with advanced disease. In all patients, [111In]T101 concentrated in pathologically or clinically detected nodes, including those in several previously unsuspected nodal regions. Concentrations (per gram of tissue) ranged from 0.01 to 0.03 percent of the injected dose and were consistently 10 to 100 times higher than previously reported on radioimmunodetection. Focal uptake was seen in skin tumors and heavily infiltrated erythroderma but not in skin plaques. The specificity of tumor targeting was documented by control studies with [111In]chloride or [111In]9.2.27 (anti-melanoma) monoclonal antibody. Increasing the T101 dose (1 to 50 mg) altered distribution in nontumor tissues. These studies suggest that imaging with [111In]T101 may be of value in identifying sites of cutaneous T-cell lymphoma. In contrast to the targeting of solid tumors, the mechanism of localization appears to be related to binding to T cells, which can then carry the radioactivity to involved sites.",
author = "Carrasquillo, {J. A.} and Bunn, {P. A.} and Keenan, {A. M.} and Reynolds, {J. C.} and Schroff, {R. W.} and Foon, {K. A.} and Su, {M. H.} and Gazdar, {A. F.} and Mulshine, {J. L.} and Oldham, {R. K.}",
year = "1986",
language = "English (US)",
volume = "315",
pages = "673--680",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "11",

}

TY - JOUR

T1 - Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody

AU - Carrasquillo, J. A.

AU - Bunn, P. A.

AU - Keenan, A. M.

AU - Reynolds, J. C.

AU - Schroff, R. W.

AU - Foon, K. A.

AU - Su, M. H.

AU - Gazdar, A. F.

AU - Mulshine, J. L.

AU - Oldham, R. K.

PY - 1986

Y1 - 1986

N2 - T101 monoclonal antibody recognizes a pan-T-cell antigen present on normal T cells and also found in high concentrations in cutaneous T-cell lymphoma. We used this antibody, radiolabeled with 111In, in gamma-camera imaging to detect sites of metastatic cutaneous T-cell lymphoma in 11 patients with advanced disease. In all patients, [111In]T101 concentrated in pathologically or clinically detected nodes, including those in several previously unsuspected nodal regions. Concentrations (per gram of tissue) ranged from 0.01 to 0.03 percent of the injected dose and were consistently 10 to 100 times higher than previously reported on radioimmunodetection. Focal uptake was seen in skin tumors and heavily infiltrated erythroderma but not in skin plaques. The specificity of tumor targeting was documented by control studies with [111In]chloride or [111In]9.2.27 (anti-melanoma) monoclonal antibody. Increasing the T101 dose (1 to 50 mg) altered distribution in nontumor tissues. These studies suggest that imaging with [111In]T101 may be of value in identifying sites of cutaneous T-cell lymphoma. In contrast to the targeting of solid tumors, the mechanism of localization appears to be related to binding to T cells, which can then carry the radioactivity to involved sites.

AB - T101 monoclonal antibody recognizes a pan-T-cell antigen present on normal T cells and also found in high concentrations in cutaneous T-cell lymphoma. We used this antibody, radiolabeled with 111In, in gamma-camera imaging to detect sites of metastatic cutaneous T-cell lymphoma in 11 patients with advanced disease. In all patients, [111In]T101 concentrated in pathologically or clinically detected nodes, including those in several previously unsuspected nodal regions. Concentrations (per gram of tissue) ranged from 0.01 to 0.03 percent of the injected dose and were consistently 10 to 100 times higher than previously reported on radioimmunodetection. Focal uptake was seen in skin tumors and heavily infiltrated erythroderma but not in skin plaques. The specificity of tumor targeting was documented by control studies with [111In]chloride or [111In]9.2.27 (anti-melanoma) monoclonal antibody. Increasing the T101 dose (1 to 50 mg) altered distribution in nontumor tissues. These studies suggest that imaging with [111In]T101 may be of value in identifying sites of cutaneous T-cell lymphoma. In contrast to the targeting of solid tumors, the mechanism of localization appears to be related to binding to T cells, which can then carry the radioactivity to involved sites.

UR - http://www.scopus.com/inward/record.url?scp=0022539135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022539135&partnerID=8YFLogxK

M3 - Article

C2 - 3489185

AN - SCOPUS:0022539135

VL - 315

SP - 673

EP - 680

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 11

ER -